Similarly, EGFR tyrosine kinase inhibitor (erlotinib) treated lung cancer cells downregulated miR21, which regulates the TNF and NF-κB signaling in mutant EGFR cells (Gong et al, 2018). This evidence concerns the gene NFKB1 and lung carcinoma.